A PROTAC-based cuproptosis sensitizer CuS-MD@CS is developed in this work, which sensitizes cells to cuprotosis by modulating the p53 pathway through the ubiquitin-proteasome systemcan. CuS-MD@CS not only can effectively deplete endogenous glutathione but also can promote the transition from glycolysis to mitochondrial respiration, thereby enhancing cancer cells' sensitivity to cuproptosis and achieving effective therapeutic effects of cuprotosis and apoptosis.

This study develops a multifunctional CRISPR-dCas9-based OMV platform termed OMV-C9I12, which facilitates the coexpression of CXCL9 and IL-12 within tumor cells. This platform enhances T cell recruitment and activation, synergizes with anti-PD-1/PD-L1 immunotherapy, and amplifies antitumor T cell immunity. This demonstrates significant therapeutic efficacy in a broad range of tumors and offers a promising strategy to overcome immunotherapy resistance.

Phos-XK, a novel hydrogel electrolyte, is crafted from xanthan gum and konjac gum through physical crosslinking and targeted phosphorylation. This design balances mechanical strength and ionic conductivity, enabling Zn//MnO₂ batteries with long cycle life and high Coulombic efficiency. Its biocompatibility and biodegradability offer a sustainable solution for flexible, wearable energy storage electronics.